C9085 – Injection, avalglucosidase alfa-ngpt, 4 mg
HCPCS Level II code · C codes: Outpatient PPS (Hospital Outpatient)
HCPCS codeC9085
- Long description
- Injection, avalglucosidase alfa-ngpt, 4 mg
- Short description
- Inj avalglucosid alfa-ngpt
- Pricing indicator
53Statute- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1EOther drugs- Added
- January 1, 2022
- Last change
- April 1, 2022 – No change
- Termination date
- March 31, 2022
Frequently asked questions
What is HCPCS code C9085?
C9085 is a HCPCS Level II code for injection, avalglucosidase alfa-ngpt, 4 mg. It was discontinued on March 31, 2022.
Does Medicare cover C9085?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby C codes
- C9077 – Injection, cabotegravir and rilpivirine, 2mg/3mg
- C9078 – Injection, trilaciclib, 1 mg
- C9079 – Injection, evinacumab-dgnb, 5 mg
- C9080 – Injection, melphalan flufenamide hydrochloride, 1 mg
- C9081 – Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9082 – Injection, dostarlimab-gxly, 100 mg
- C9083 – Injection, amivantamab-vmjw, 10 mg
- C9084 – Injection, loncastuximab tesirine-lpyl, 0.1 mg
- C9086 – Injection, anifrolumab-fnia, 1 mg
- C9087 – Injection, cyclophosphamide, (auromedics), 10 mg
- C9088 – Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
- C9089 – Bupivacaine, collagen-matrix implant, 1 mg
- C9090 – Injection, plasminogen, human-tvmh, 1 mg
- C9091 – Injection, sirolimus protein-bound particles, 1 mg
- C9092 – Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
- C9093 – Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.